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Patients with congestive heart failure (CHF) frequently
become anemic. In this review, we will examine the possi-
ble etiologies for anemia in heart failure, discuss the
cardiovascular consequences of anemia, the effect of
anemia on prognosis and exercise capacity, as well as
the potential benefits of anemia treatment in this patient
population.
Etiology of anemia in CHF
The etiology of anemia in patients with congestive
heart failure (CHF) is multifactorial and may result from
any one or combination of the following factors: chronic
disease state, malnutrition, hemodilution from volume
overload, medical therapy such as angiotensin enzyme-
converting (ACE) inhibition, or elevated cytokine pro-
duction [1–4].
Similar to the anemia of chronic disease, anemia in
heart failure patients is characterized by normal red
blood cell morphology and normal iron stores and may
be in part mediated by the actions of pro-inflammatory
cytokines [4]. Cytokines can reduce red blood cell vol-
ume by suppressing erythropoietin production and eryth-
ropoiesis in the bone marrow, reducing availability of
tissue iron stores for incorporation into hemoglobin, and
decreasing red blood cell survival time in the circulation.
Pro-inflammatory cytokine activity is increased in pa-
tients with CHF in proportion to the severity of symp-
toms and is associated with increased mortality [5].
Whether cytokine activation is causally linked to anemia
in patients with CHF is unknown.
Heart failure results in decreased renal perfusion,
which ultimately results in sodium retention and volume
overload. Plasma volume is commonly increased above
normal values even in non-edematous treated patients
with CHF. Accordingly, hemodilution secondary to
plasma volume expansion may also contribute to de-
creased hematocrit in patients with heart failure. A small
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study used blood volume analysis to identify the preva-
lence of hemodilution versus reduced red blood cell vol-
ume in 37 anemic patients with heart failure [6]. I131
serum albumin was injected into a peripheral vein and
serial blood sampling was performed for 36 minutes.
Spun hematocrit was determined from each sample and
plasma radioactivity was measured in an automated
counter. Plasma volume was estimated from the volume
of distribution of the albumin. Blood and RBC volume
were approximated from the spun hematocrit and com-
pared for normal values of sex, height, and weight. Pa-
tients were considered to have hemodilution and not
true anemia if the RBC volume was greater than 95%
of the predicted value. Seventeen patients (46%) had
hemodilution. Blood volume analysis indicated that
hemodilution accounts for nearly half of the anemia ob-
served in patients with advanced heart failure [6].
Medical therapy such as ACE inhibition can result in
down-regulation of erythropoietin production [3]. Iron
deficiency from prophylactic aspirin intake or from intes-
tinal malabsorption can also contribute to anemia in
patients with heart failure. Recent evidence suggests that
celiac disease is more common in patients with idiopathic
dilated cardiomyopathy [7]. Associated renal insuffi-
ciency can also result in the development of anemia in
these patients [8].
Anemia as a prognostic factor in CHF
Several studies have shown a high prevalence of ane-
mia in patients with all stages of heart failure [9–13].
Seventeen percent of 12,065 patients admitted with new
onset heart failure were found to be anemic [9]. In a
recent study examining the prevalence of anemia in an
elderly patient cohort with CHF, 48% of the patients had
hematocrits below 37% [10]. The prevalence of anemia
increases with the severity of disease [6, 11, 12]. At our
center, the prevalence of anemia rises from 33% in pa-
tients with Class II (New York Heart Association
functional class) CHF to 70% in patients with Class IV
CHF [6].
Recently, anemia has been identified as a poor prog-
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nostic indicator in all classes of patients with heart failure
[6, 8–13]. Retrospective evaluation of the Study of Left
Ventricular Dysfunction (SOLVD) database has shown
anemia to be an independent risk factor for mortality in
patients with left ventricular dysfunction. In a study of
1061 patients with Class II-IV CHF and left ventricular
ejection fraction less than 40% followed at an academic
heart failure center, low hemoglobin was an independent
predictor of mortality [12]. Similarly, in a large commu-
nity-based population of patients with heart failure, ane-
mia was an independent prognostic factor for mortality
[9]. In an elderly patient population (age 65 years)
recently admitted with heart failure, the presence of ane-
mia was associated with increased risk for re-hospitaliza-
tion and death [10].
A recent study examining the prevalence of hemodilu-
tion in patients with advanced heart failure also investi-
gated the survival of patients with true anemia and hemo-
dilution [6]. In patients with true anemia as well as
hemodilution, mortality was increased compared to non-
anemic heart failure patients. However, hemodilution
was associated with the worst survival. Hypervolemia
has been linked to increased mortality risk in patients
with heart failure since brain natruretic peptide (BNP),
a cardiac-derived hormone closely correlated to left ven-
tricular end-diastolic pressure, [14] has been shown to
be an independent predictor of survival in these patients.
Although the number of patients in this study was small,
the implication is that volume overload may be a key
mechanism contributing to the increased mortality in
anemic patients with heart failure. How correction of
anemia in patients with heart failure affects survival is
presently unknown.
Pathophysiologic response to anemia
The normal hemodynamic responses to chronic ane-
mia include increased cardiac output, decreased systemic
vascular resistance, widened arteriovenous oxygen gradi-
ent, and increased plasma volume [15, 16]. In patients
with CHF, these hemodynamic responses are impaired,
as cardiac output reserve is limited in response to sympa-
thetic stimulation, vasodilatory reserve is reduced, and
oxygen extraction in exercising skeletal muscle is already
maximal in non-anemic patients. Hemodynamic responses
to anemia may have adverse effects on ventricular struc-
ture and function, as increased preload secondary to veno-
constriction and plasma volume expansion may contribute
to chronic left ventricular remodeling and exacerbation
of preload-dependent mitral insufficiency. Anemia may
also precipitate myocardial ischemia in patients with epi-
cardial coronary artery disease, and subendocardial hypo-
perfusion in patients with left ventricular hypertrophy
[17–20].
The cardiovascular demands of anemia may serve to
further exacerbate myocardial and peripheral hypoxia,
Table 1. Effect of erythropoietin on hemoglobin levels and exercise
performance in patients with chronic renal failure
Change in Change in VO2
Author Subjects N Hb g/dL mL/kg/min
[27] 19 7–12 15.3–17.8
[26] 8 5.9–10.9 16–23
[28] 10 7.1–9.8 15.1–22.7
[29] 39 6–10 22.4–27.0
[30] 20 6–11 18.7–22
increased venous return, and cardiac work. This in turn
may lead to additional activation of neurohormones and
cytokines. Cytokines can further exacerbate anemia by
direct bone marrow suppression. A cycle of worsening
anemia can occur, which has been called the Cardio
Renal Anemia syndrome. Normalization of hemoglobin
concentration in patients with CHF may interrupt this
cycle [21].
Anemia treatment in CHF
Though anemia is frequently noted in patients with
CHF, it is often untreated, despite the fact that the pri-
mary symptoms of heart failure (i.e., dyspnea, fatigue,
and exercise intolerance) can all be exacerbated by ane-
mia. The effect of correction of anemia on exercise per-
formance has not been well studied in these patients.
The impact of anemia on exercise performance has
been studied in normal subjects before and after transfu-
sion [22]. The change in maximal oxygen consumption
(VO2) is proportional to the change in hemoglobin as
would be anticipated from the Fick equation (i.e., VO2
Cardiac output  the arteriovenous oxygen difference).
Re-infusion of autologous erythrocytes (i.e., blood dop-
ing) has also been shown to enhance exercise perfor-
mance [23]. With the availability of human recombinant
erythropoietin, the effect of this agent on exercise perfor-
mance has been evaluated in normal subjects and ath-
letes. Small studies have demonstrated the efficacy of
this drug on peak exercise performance and endurance
[24, 25]. Indeed, surreptitious use of erythropoietin has
been used by athletes as a performance-enhancing drug.
The mechanism by which erythropoietin improves exer-
cise capacity is presumed to be increased oxygen delivery
from higher hemoglobin levels.
Several small studies have shown improvement in ex-
ercise capacity in chronic renal failure patients with
erythropoietin treatment (Table 1) [26–30]. Lactate, pyr-
uvate, and excess lactate levels at end-exercise and recov-
ery were attenuated in dialysis patients after treatment
with erythropoietin, implying better muscle oxygenation
with less reliance on anaerobic metabolism [31]. The
hemodynamic effects of erythropoietin therapy in pa-
tients with renal failure include a reduction in cardiac
output, increase in arterial blood pressure, and thus, an
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Table 2. Maximal and submaximal exercise capacity at baseline and end of study
Control (N  8) Erythropoietin (N  15)
Baseline End Baseline End
Rest Exercise Rest Exercise Rest Exercise Rest Exercise
HR bpm 779 10019 8111 10222 769 10614 737 10213
BP mm Hg 888 969 818 9010 878 9412 878 9415
RQ 0.830.04 1.140.11 0.880.07 1.100.11 0.840.06 1.130.08 0.850.07 1.100.08
VO2 mL/kg/min 10.01.9 9.51.6 11.01.8 12.72.8a
VO2 AT mL/kg/min 8.21.2 7.10.8 7.51.1 8.71.9a
Exercise duration seconds 542115 459172 590107 657119a
6-minute walk distance feet 929356 1052403 1187279 1328254
Abbreviations are: HR, heart rate; BP, mean blood pressure; RQ, respiratory quotient; VO2, oxygen consumption; VO2 AT, oxygen consumption at anaerobic
threshold.
a P  0.05 rest vs. exercise; b P  0.004 rest vs. exercise
increase in peripheral resistance [32]. Measurement of
leg blood flow using thermodilution technique also showed
reduced resting and exercise limb perfusion following
erythropoietin treatment; however, this decrement in
perfusion is offset by the increase in hemoglobin, re-
sulting in overall increase in limb oxygenation [33].
Muscle strength and endurance in chronic renal failure
patients has also been shown to be enhanced by treat-
ment with erythropoietin in 2 studies where quadriceps
strength was measured with an isokinetic dynanometer
[27, 34]. Peak muscle torque increased and fatigue les-
sened with treatment. Correction of anemia should not
effect muscle strength, as isometric exercise is primarily
dependent on anaerobic metabolism and muscle mass.
This beneficial effect of erythropoietin on muscle func-
tion may be derived from increased activity levels from
enhanced functional capacity and/or by an alternative
previously unrecognized beneficial effect on muscle func-
tion, such as an anti-apototic effect.
Unlike anemia of chronic renal disease, erythropoietin
levels may be slightly elevated in heart failure subjects
[35]. Increased erythropoietin levels in patients with
heart failure may be related to decreased renal cortical
perfusion, leading to local tissue hypoxia [36]. However,
the erythropoietin levels are in a range that treatment
with erythropoietin may still provide benefit.
Previous reports describe improvement in functional
class and left ventricular ejection fraction, as well as a
reduction in hospitalizations in patients with CHF
treated with erythropoietin and intravenous iron [11, 20].
In another article in this supplement, the results of these
studies are well described.
We recently studied the effect of erythropoietin on
exercise performance in a group of anemic patients with
advanced heart failure [37]. Twenty-six anemic patients
with Class II –IV heart failure participated in a random-
ized, controlled, single, blind, prospective study. Patients
with severe heart failure were randomized 2:1 to receive
therapy with 15,000 to 30,000 IU of erythropoietin
weekly versus placebo. Six-minute walk tests and peak
oxygen consumption were measured at baseline and fol-
lowing 2 to 3 months of therapy. The patients treated
with erythropoietin had a significant increase in hemo-
globin from 11.0 to 14.3 g/dL. A significant improvement
in submaximal and maximal exercise capacity in anemic
heart failure patients receiving erythropoietin and oral
iron supplements was demonstrated. Peak VO2, VO2 at
the anaerobic threshold, exercise duration, and 6-minute
walk distance all increased significantly in the erythro-
poietin treated patients but not in the control group
(Table 2).
The mechanism by which erythropoietin improves ex-
ercise capacity in patients with chronic disease is not
fully known. As discussed previously, in normal subjects
and athletes this mechanism is presumed to be increased
oxygen delivery from higher hemoglobin levels. In dis-
ease states, alternative mechanisms may also be oper-
ative. For example, elevated hemoglobin levels may
decrease oxidative stress by scavenging oxygen-free radi-
cals. This in turn may improve endothelial function, in-
crease skeletal muscle perfusion, and thereby improve
oxygen delivery. To directly evaluate the effects of eryth-
ropoietin on peripheral vascular resistance in the skeletal
muscle circulation, forearm vascular resistance at rest
and after 5 minutes of transient arterial occlusion was
determined with venous occlusion plethysmography in a
subset of 21 patients. In contrast to previous investigators
[38], no change was observed in resting or peak exercise
blood pressure in patients after receiving erythropoietin
therapy. Forearm vascular resistance at rest and in re-
sponse to transient ischemia did not change during the
course of the trial in either the control or treated group,
and did not differ between groups. This response was
different from that observed in renal failure patients,
in which erythropoietin treatment increased peripheral
resistance.
Applying the Fick equation, one would predict pro-
portional changes in hemoglobin and VO2 if we assume
peak exercise cardiac output and the arterial-venous oxy-
gen difference to be constant during the course of the
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treatment. In our study, only a minority of patients exhib-
ited parallel increases in hemoglobin and VO2. In most
patients, the increment in hemoglobin was much greater
than the improvement in peak VO2. This is analogous
to observations in chronic hemodialysis patients in which
the increment in peak VO2 is also less than anticipated
from the magnitude of improvement in the hematocrit
[27, 30]. The increase in oxygen consumption/g of hemo-
globin calculates to 189 mL/min in normal subjects [25]
versus 37 mL/min in renal failure [27] and 35 mL/min
in CHF subjects [37]. These findings suggest that an
intrinsic muscle or vascular abnormality precludes opti-
mal oxygen utilization. Muscle metabolic abnormalities
have been described in patients with heart failure [39]
and in patients with renal failure [40]. These muscle
metabolic abnormalities are partially due to decondition-
ing from chronic disease, but other factors such as persis-
tent catecholamine stimulation and/or cytokine effects
may also be contributing to the metabolic abnormalities.
One factor that may have impacted on the less than
anticipated improvement in exercise capacity in our
heart failure subjects may have been the relatively short
duration of therapy. Hemoglobin levels rapidly in-
creased, resulting in an average duration of erythropoie-
tin therapy of only 10 weeks. The chronic skeletal muscle
changes that impair oxygen utilization may require more
sustained therapy to reverse. However, in patients with
renal failure receiving erythropoietin therapy, short- (3
months) and long-term (12 months) improvement in ex-
ercise capacity is comparable.
In our study, we examined the rate of oxygen utiliza-
tion by the peripheral muscle using post-exercise oxygen
recovery kinetics and near infrared spectroscopy. Both
of these techniques provide a non-invasive assessment
of the rate of muscle oxidative metabolism. Recovery
half times for both techniques remained prolonged and
unaffected by erythropoietin treatment [37]. The only
documented mechanism for improved performance in
this study was increased oxygen delivery from increased
hemoglobin concentration.
Marrades [33] estimated the conductance of oxygen
transfer from the microcirculation to the mitochondria
in 8 patients with renal failure and found a reduced
conductance in these patients, which was only slightly
improved by erythropoietin treatment.
One concern regarding use of erythropoietin in pa-
tients with heart failure was whether this therapy would
result in significant volume overload. In a subgroup of
our treated patients, plasma and red blood cell volume
were determined by the 131I-radioiodinated serum albu-
min technique. Increased blood volume was observed
in all patients but this was not further increased with
treatment. These measurements revealed a shift in blood
composition such that plasma volume was reduced while
red blood cell volume increased. This shift occurred with-
out any intensification of diuretic therapy [37].
Changes in central cardiac function such as regression
of left ventricular mass and/or an increase in left ventric-
ular ejection fraction in response to erythropoietin ther-
apy have been described [18, 21]. The potential effect of
central hemodynamic improvement on exercise capacity
from erythropoietin therapy has not been investigated.
CONCLUSION
Many questions remain to be addressed regarding the
use of erythropoietin in patients with heart failure. Dura-
tion of therapy, dosing, and target hemoglobin levels
remain to be clarified. The mechanism by which erythro-
poietin improves exercise capacity also needs further
investigation. Nonetheless, preliminary studies suggest
that correction of anemia with erythropoietin effectively
increases exercise capacity and improves quality of life
in these patients. Currently, a double-blind, randomized,
placebo-controlled, multicenter trial using darbepoietin
alfa in 300 anemic heart failure is being conducted. Exer-
cise tolerance, measured as change in maximal exercise
duration following 6 months of therapy) is the primary
end point of the study. Secondary end points include
1-year survival, quality of life, and the patient’s global
assessment. So far, more than 100 patients have entered
into this trial. Undoubtedly, the results of this study
will yield important information on how erythropoietin
therapy will be integrated into the routine care of pa-
tients with heart failure.
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